Sponsor Overview
Explore verified public information about Conjupro Biotherapeutics Inc.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 1 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 1 supporting sources.
“To address this need, Conjupro Biotherapeutics Inc. offers expanded access for our investigational drug CPO301 (also known as SYS 6010), an antibody conjugate (ADC) targeting EGFR in NSCLC.”
Reagan-Udall Foundation Insights
Single-Patient EA Policies/Criteria Eligibility Criteria: To be eligible for Expanded Access, patients must meet the following criteria: • Have a serious or life-threatening condition for which no satisfactory alternative treatments are available. • Be unable to participate in ongoing clinical trials. • There is sufficient clinical data available with respect to both the investigational drug and the disease condition for which the application is being sought, to anticipate that any potential benefits from treatment are likely to outweigh any potential risks to the patient. • Conjupro must have an adequate supply of the investigational drug. Available Therapies via Single-Patient EA CPO301
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.